Guidelines for depot antipsychotic treatment in schizophrenia

John M. Kane, Eugenio Aguglia, A. Carlo Altamura, José Luis Ayuso Gutierrez, Nicoletta Brunello, W. Wolfgang Fleischhacker, Wolfang Gaebel, Jes Gerlach, Julien D. Guelfi, Werner Kissling, Yvon D. Lapierre, Eva Lindström, Julien Mendlewicz, Giorgio Racagni, Luis Salvador Carulla, Nina R. Schooler

Research output: Contribution to journalArticle

282 Citations (Scopus)

Abstract

These guidelines for depot antipsychotic treatment in schizophrenia were developed during a two-day consensus conference held on July 29 and 30, 1995 in Siena, Italy. Depot antipsychotic medications were developed in the 1960s as an attempt to improve the long-term treatment of schizophrenia (and potentially other disorders benefiting from long-term antipsychotic medication). Depot drugs as distinguishable from shorter acting intramuscularly administered agents can provide a therapeutic concentration of at least a seven day duration in one parenteral dose. The prevention of relapse in schizophrenia remains an enormous public health challenge worldwide and improvements in this area can have tremendous impact on morbidity, mortality and quality of life, as well as direct and indirect health care costs. Though there has been debate as to what extent depot (long-acting injectable) antipsychotics are associated with significantly fewer relapses and rehospitalizations, in our view when all of the data from individual trials and metaanalyses are taken together, the findings are extremely compelling in favor of depot drugs. However in many countries throughout the world fewer than 20% of individuals with schizophrenia receive these medications. The major advantage of depot antipsychotics over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among patients with schizophrenia and is a frequent cause of relapse. In terms of adverse effects, there are not convincing data that depot drugs are associated with a significantly higher incidence of adverse effects than oral drugs. Therefore in our opinion any patient for whom long-term antipsychotic treatment is indicated should be considered for depot drugs. In choosing which drug the clinician should consider previous experience, personal patient preference, patients history of response (both therapeutic and adverse effects) and pharmacokinetic properties. In conclusion the use of depot antipsychotics has important advantages in facilitating relapse prevention. Certainly pharmacotherapy must be combined with other treatment modalities as needed, but the consistent administration of the former is often what enables the latter.

Original languageEnglish
Pages (from-to)55-66
Number of pages12
JournalEuropean Neuropsychopharmacology
Volume8
Issue number1
DOIs
Publication statusPublished - Feb 1 1998

Fingerprint

Antipsychotic Agents
Schizophrenia
Guidelines
Pharmaceutical Preparations
Secondary Prevention
Therapeutics
Recurrence
Medication Adherence
Patient Preference
Therapeutic Uses
Health Care Costs
Italy
Consensus
Pharmacokinetics
Public Health
Quality of Life
Morbidity
Drug Therapy
Injections
Mortality

Keywords

  • Depot antipsychotics
  • Relapse
  • Schizophrenia
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Kane, J. M., Aguglia, E., Altamura, A. C., Gutierrez, J. L. A., Brunello, N., Fleischhacker, W. W., ... Schooler, N. R. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology, 8(1), 55-66. https://doi.org/10.1016/S0924-977X(97)00045-X

Guidelines for depot antipsychotic treatment in schizophrenia. / Kane, John M.; Aguglia, Eugenio; Altamura, A. Carlo; Gutierrez, José Luis Ayuso; Brunello, Nicoletta; Fleischhacker, W. Wolfgang; Gaebel, Wolfang; Gerlach, Jes; Guelfi, Julien D.; Kissling, Werner; Lapierre, Yvon D.; Lindström, Eva; Mendlewicz, Julien; Racagni, Giorgio; Carulla, Luis Salvador; Schooler, Nina R.

In: European Neuropsychopharmacology, Vol. 8, No. 1, 01.02.1998, p. 55-66.

Research output: Contribution to journalArticle

Kane, JM, Aguglia, E, Altamura, AC, Gutierrez, JLA, Brunello, N, Fleischhacker, WW, Gaebel, W, Gerlach, J, Guelfi, JD, Kissling, W, Lapierre, YD, Lindström, E, Mendlewicz, J, Racagni, G, Carulla, LS & Schooler, NR 1998, 'Guidelines for depot antipsychotic treatment in schizophrenia', European Neuropsychopharmacology, vol. 8, no. 1, pp. 55-66. https://doi.org/10.1016/S0924-977X(97)00045-X
Kane, John M. ; Aguglia, Eugenio ; Altamura, A. Carlo ; Gutierrez, José Luis Ayuso ; Brunello, Nicoletta ; Fleischhacker, W. Wolfgang ; Gaebel, Wolfang ; Gerlach, Jes ; Guelfi, Julien D. ; Kissling, Werner ; Lapierre, Yvon D. ; Lindström, Eva ; Mendlewicz, Julien ; Racagni, Giorgio ; Carulla, Luis Salvador ; Schooler, Nina R. / Guidelines for depot antipsychotic treatment in schizophrenia. In: European Neuropsychopharmacology. 1998 ; Vol. 8, No. 1. pp. 55-66.
@article{fe8c1044566640d98123e24b8a16f084,
title = "Guidelines for depot antipsychotic treatment in schizophrenia",
abstract = "These guidelines for depot antipsychotic treatment in schizophrenia were developed during a two-day consensus conference held on July 29 and 30, 1995 in Siena, Italy. Depot antipsychotic medications were developed in the 1960s as an attempt to improve the long-term treatment of schizophrenia (and potentially other disorders benefiting from long-term antipsychotic medication). Depot drugs as distinguishable from shorter acting intramuscularly administered agents can provide a therapeutic concentration of at least a seven day duration in one parenteral dose. The prevention of relapse in schizophrenia remains an enormous public health challenge worldwide and improvements in this area can have tremendous impact on morbidity, mortality and quality of life, as well as direct and indirect health care costs. Though there has been debate as to what extent depot (long-acting injectable) antipsychotics are associated with significantly fewer relapses and rehospitalizations, in our view when all of the data from individual trials and metaanalyses are taken together, the findings are extremely compelling in favor of depot drugs. However in many countries throughout the world fewer than 20{\%} of individuals with schizophrenia receive these medications. The major advantage of depot antipsychotics over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among patients with schizophrenia and is a frequent cause of relapse. In terms of adverse effects, there are not convincing data that depot drugs are associated with a significantly higher incidence of adverse effects than oral drugs. Therefore in our opinion any patient for whom long-term antipsychotic treatment is indicated should be considered for depot drugs. In choosing which drug the clinician should consider previous experience, personal patient preference, patients history of response (both therapeutic and adverse effects) and pharmacokinetic properties. In conclusion the use of depot antipsychotics has important advantages in facilitating relapse prevention. Certainly pharmacotherapy must be combined with other treatment modalities as needed, but the consistent administration of the former is often what enables the latter.",
keywords = "Depot antipsychotics, Relapse, Schizophrenia, Treatment",
author = "Kane, {John M.} and Eugenio Aguglia and Altamura, {A. Carlo} and Gutierrez, {Jos{\'e} Luis Ayuso} and Nicoletta Brunello and Fleischhacker, {W. Wolfgang} and Wolfang Gaebel and Jes Gerlach and Guelfi, {Julien D.} and Werner Kissling and Lapierre, {Yvon D.} and Eva Lindstr{\"o}m and Julien Mendlewicz and Giorgio Racagni and Carulla, {Luis Salvador} and Schooler, {Nina R.}",
year = "1998",
month = "2",
day = "1",
doi = "10.1016/S0924-977X(97)00045-X",
language = "English",
volume = "8",
pages = "55--66",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "1",

}

TY - JOUR

T1 - Guidelines for depot antipsychotic treatment in schizophrenia

AU - Kane, John M.

AU - Aguglia, Eugenio

AU - Altamura, A. Carlo

AU - Gutierrez, José Luis Ayuso

AU - Brunello, Nicoletta

AU - Fleischhacker, W. Wolfgang

AU - Gaebel, Wolfang

AU - Gerlach, Jes

AU - Guelfi, Julien D.

AU - Kissling, Werner

AU - Lapierre, Yvon D.

AU - Lindström, Eva

AU - Mendlewicz, Julien

AU - Racagni, Giorgio

AU - Carulla, Luis Salvador

AU - Schooler, Nina R.

PY - 1998/2/1

Y1 - 1998/2/1

N2 - These guidelines for depot antipsychotic treatment in schizophrenia were developed during a two-day consensus conference held on July 29 and 30, 1995 in Siena, Italy. Depot antipsychotic medications were developed in the 1960s as an attempt to improve the long-term treatment of schizophrenia (and potentially other disorders benefiting from long-term antipsychotic medication). Depot drugs as distinguishable from shorter acting intramuscularly administered agents can provide a therapeutic concentration of at least a seven day duration in one parenteral dose. The prevention of relapse in schizophrenia remains an enormous public health challenge worldwide and improvements in this area can have tremendous impact on morbidity, mortality and quality of life, as well as direct and indirect health care costs. Though there has been debate as to what extent depot (long-acting injectable) antipsychotics are associated with significantly fewer relapses and rehospitalizations, in our view when all of the data from individual trials and metaanalyses are taken together, the findings are extremely compelling in favor of depot drugs. However in many countries throughout the world fewer than 20% of individuals with schizophrenia receive these medications. The major advantage of depot antipsychotics over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among patients with schizophrenia and is a frequent cause of relapse. In terms of adverse effects, there are not convincing data that depot drugs are associated with a significantly higher incidence of adverse effects than oral drugs. Therefore in our opinion any patient for whom long-term antipsychotic treatment is indicated should be considered for depot drugs. In choosing which drug the clinician should consider previous experience, personal patient preference, patients history of response (both therapeutic and adverse effects) and pharmacokinetic properties. In conclusion the use of depot antipsychotics has important advantages in facilitating relapse prevention. Certainly pharmacotherapy must be combined with other treatment modalities as needed, but the consistent administration of the former is often what enables the latter.

AB - These guidelines for depot antipsychotic treatment in schizophrenia were developed during a two-day consensus conference held on July 29 and 30, 1995 in Siena, Italy. Depot antipsychotic medications were developed in the 1960s as an attempt to improve the long-term treatment of schizophrenia (and potentially other disorders benefiting from long-term antipsychotic medication). Depot drugs as distinguishable from shorter acting intramuscularly administered agents can provide a therapeutic concentration of at least a seven day duration in one parenteral dose. The prevention of relapse in schizophrenia remains an enormous public health challenge worldwide and improvements in this area can have tremendous impact on morbidity, mortality and quality of life, as well as direct and indirect health care costs. Though there has been debate as to what extent depot (long-acting injectable) antipsychotics are associated with significantly fewer relapses and rehospitalizations, in our view when all of the data from individual trials and metaanalyses are taken together, the findings are extremely compelling in favor of depot drugs. However in many countries throughout the world fewer than 20% of individuals with schizophrenia receive these medications. The major advantage of depot antipsychotics over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among patients with schizophrenia and is a frequent cause of relapse. In terms of adverse effects, there are not convincing data that depot drugs are associated with a significantly higher incidence of adverse effects than oral drugs. Therefore in our opinion any patient for whom long-term antipsychotic treatment is indicated should be considered for depot drugs. In choosing which drug the clinician should consider previous experience, personal patient preference, patients history of response (both therapeutic and adverse effects) and pharmacokinetic properties. In conclusion the use of depot antipsychotics has important advantages in facilitating relapse prevention. Certainly pharmacotherapy must be combined with other treatment modalities as needed, but the consistent administration of the former is often what enables the latter.

KW - Depot antipsychotics

KW - Relapse

KW - Schizophrenia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0031983904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031983904&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(97)00045-X

DO - 10.1016/S0924-977X(97)00045-X

M3 - Article

C2 - 9452941

AN - SCOPUS:0031983904

VL - 8

SP - 55

EP - 66

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 1

ER -